Skip to main content

Advertisement

SpringerLink
Log in

Management of Intracerebral Hemorrhage: Update and Future Therapies

  • Stroke (H. Diener, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Intracerebral hemorrhage (ICH) represents about 15% of all strokes in the USA, but almost 50% of fatal strokes. There are many causes of ICH, but the most common are hypertension and cerebral amyloid angiopathy. This review will discuss new advances in the treatment of intracerebral hemorrhage.

Recent Findings

The treatment of ICH focuses on management of edema, aggressive blood pressure reduction, and correction of coagulopathy. Early initiation of supportive medical therapies, including blood pressure management, in a neurological intensive care unit reduces mortality, but at present there is no definitive, curative therapy analogous to mechanical thrombectomy for ischemic stroke. Nonetheless, new medical and surgical approaches promise more successful management of ICH patients, especially new approaches to surgical management.

Summary

In this review, we focus on the current standard of care of acute ICH and discuss emerging therapies that may alter the landscape of this devastating disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8:355–69.

    Article  PubMed  Google Scholar 

  2. Kirshner HS. Medical management of intracerebral hemorrhage: back to the basics. Int J Clin Pract. 2008;62(4):521–2.

    Article  CAS  PubMed  Google Scholar 

  3. •• Schrag M, Kirshner H. Management of intracerebral hemorrhage: JACC Focus Seminar. J Am Coll Cardiol .2020. 75:1819–31. This is a more comprehensive review of ICH

  4. Flaherty ML, Woo D, Haverbusch M, et al. Racial variations in location and risk of intracerebral hemorrhage. Stroke. 2005;36:934–7.

    Article  PubMed  Google Scholar 

  5. Dye JA, Rees G, Yang I, Vespa PM, Martin NA, Vinters HV. Neuropathologic analysis of hematomas evacuated from patients with spontaneous intracerebral hemorrhage. Neuropathology. 2014;34:253–60.

    Article  PubMed  Google Scholar 

  6. Dowlatshahi D, Demchuk AM, Flaherty ML, Ali M, Lyden PL, Smith EE. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology. 2011;76(14):1238–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Vinters HV. Cerebral amyloid angiopathy: a critical review. Stroke. 1987;18(2):311–24.

    Article  CAS  PubMed  Google Scholar 

  8. Greenberg SM, Rebeck GW, Vonsattel JPG, et al. Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995;38(2):254–9.

    Article  CAS  PubMed  Google Scholar 

  9. Doden T, Sato H, Sasahara E, et al. Clinico-radiological characteristics and pathological diagnosis of cerebral amyloid angiopathy-related intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2016;25(7):1736–45.

    Article  PubMed  Google Scholar 

  10. Schrag M, McAuley G, Pomakian J, et al. Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol. 2010;119(3):291–302.

    Article  PubMed  PubMed Central  Google Scholar 

  11. • Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston criteria. Stroke. 2018. 49(2):491–497. Definitive article on criteria for diagnosis of CAA

  12. Schrag M, Kirshner H. Neuropsychological effects of cerebral amyloid angiopathy. Curr Neurol Neurosci Reports. 2016;16(8):76.

    Article  CAS  Google Scholar 

  13. Kase CS, Robinson RK, Stein RW, et al. Anticoagulant-related intracerebral hemorrhage. Neurology. 1985;35:943–8.

    Article  CAS  PubMed  Google Scholar 

  14. Schrag M, Greer D. Clinical associations of cerebral microbleeds on magnetic resonance neuroimaging. J Stroke Cerebrovasc Dis. 2014;23(10):2489–97.

    Article  PubMed  Google Scholar 

  15. Malhotra A, Schindler J, MacGrory B, et al. Cerebral microhemorrhages and meningeal siderosis in infective endocarditis. Cerebrovasc Dis. 2017;43:59–67.

    Article  PubMed  Google Scholar 

  16. Wagner I, Hauer E, Staykov D, et al. Effects of continuous hypertonic saline infusion on peri-hemorrhagic edema evolution. Stroke. 2011;42:1540–5.

    Article  PubMed  Google Scholar 

  17. Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:2032–60.

    Article  PubMed  Google Scholar 

  18. Wada R, Aviv RI, Fox AJ, et al. CT angiography “spot sign” predicts hematoma expansion in acute intracerebral hemorrhage. Stroke. 2007;38(4):1257–62.

    Article  PubMed  Google Scholar 

  19. Poungvarin N, Bhoopat W, Viriyavejakul A, et al. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. New Engl J Med. 1987;316:1229–33.

    Article  CAS  PubMed  Google Scholar 

  20. GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;19:439–58.

    Google Scholar 

  21. Fisher CM, Picard EH, Polak A, et al. Acute hypertensive cerebellar hemorrhage: diagnosis and surgical treatment. J Nerv Ment Dis. 1965;140:38–57.

    Article  CAS  PubMed  Google Scholar 

  22. Ott KH, Kase CS, Ojemann RG, Mohr JP. Cerebellar hemorrhage: diagnosis and treatment. A review of 56 cases. Arch Neurol. 1974;31:160–7.

    Article  CAS  PubMed  Google Scholar 

  23. McKissock W, Richardson A, Taylor J. Primary intracerebral haemorrhage: a controlled trial for surgical and conservative treatment in 180 unselected cases. Lancet. 1961;278:221–6.

    Article  Google Scholar 

  24. Auer LM, Deinsberger W, Niederkorn K, et al. Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: a randomized study. J Neurosurg. 1989;70:530–5.

    Article  CAS  PubMed  Google Scholar 

  25. Juvela S, Heiskanen O, Poranen A, et al. The treatment of spontaneous intracerebral hemorrhage: a prospective randomized trial of surgical and conservative treatment. J Neurosurg. 1989;70(5):755–8.

    Article  CAS  PubMed  Google Scholar 

  26. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomized trial. Lancet. 2005;365:387–97.

    Article  PubMed  Google Scholar 

  27. Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICHII): a randomized trial. Lancet. 2013;382:397–408.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Naidech AM, Garg RK, Liebling S, et al. Anticonvulsant use and outcomes after intracerebral hemorrhage. Stroke. 2009;40(12):3810–5.

    Article  CAS  PubMed  Google Scholar 

  29. Gilmore E, Maciel C, Hirsch L, Sheth K. Review of the utility of prophylactic anticonvulsant use in critically ill patients with intracerebral hemorrhage. Stroke. 2016;47:2666–72.

    Article  PubMed  Google Scholar 

  30. Tietjen C, Hurn P, Ulatowski JA, Kirsch J. Treatment modalities for hypertensive patients with intracranial pathology: options and risks. Crit Care Med. 1996;24(2):311–22.

    Article  CAS  PubMed  Google Scholar 

  31. • Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. New England Journal of Medicine. 2013. 368:2355–2365. This is a critical study on blood pressure lowering for ICH

  32. • Qureshi A, Palesch Y, Barsan W, et al. Intensive blood pressure lowering in patients with acute cerebral hemorrhage. New England Journal of Medicine. 2016. 375:1033–1043. Another pivotal study on blood pressure lowering

  33. Moullaali TJ, Wang X, Martin RH, et al. Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. Lancet Neurol. 2019;18(9):857–64.

    Article  PubMed  Google Scholar 

  34. Mayer S, Brun N, Broderick J, et al. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocrit Care. 2006;4(3):206–14.

    Article  CAS  PubMed  Google Scholar 

  35. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated Factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127–37.

    Article  CAS  PubMed  Google Scholar 

  36. Rehmani R, Han A, Hassan J, Farkas J. Role of prothrombin complex concentrate (PCC) in acute intracerebral hemorrhage with positive CTA spot sign: An institutional experience at a regional and state designated stroke center. Emerg Radiol. 2017;24:241–7.

    Article  PubMed  Google Scholar 

  37. Poli S, Hartig F, Selim MH, et al. Prothrombin complex concentrates use in intracerebral hemorrhage. Stroke. 2017;48:2644–6.

    Article  PubMed  Google Scholar 

  38. Gerner ST, Kuramatsu JB, Sembill JA, et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol. 2018;83:186–96.

    Article  CAS  PubMed  Google Scholar 

  39. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal-Full cohort analysis. N Engl J Med. 2017;377:431–41.

    Article  CAS  PubMed  Google Scholar 

  40. Connolly SJ, Crowther M, Eikelboom JW. Full study report of Andexanet Alfa for bleeding associated with Factor Xa inhibitors. N Engl J Med. 2019;380(14):1326–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Baharoglu MI, Cordonnier C, Salman RA, et al. Platelet transfusions versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomized, open-label, phase 3 trial. Lancet. 2016;387(10038):2605–13.

    Article  PubMed  Google Scholar 

  42. Li X, Sun Z, Zhao W, et al. Effect of acetylcaslicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage. J Neurosurg. 2013;118(1):94–103.

    Article  CAS  PubMed  Google Scholar 

  43. Hedges S, Dehoney SB, Hooper JS, Amanzadeh J, Busti A. Evidence based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol. 2007;3(3):138–53.

    Article  CAS  PubMed  Google Scholar 

  44. Mannucci M, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med. 1983;308:8–12.

    Article  CAS  PubMed  Google Scholar 

  45. Yaghi S, Willey JZ, Cucchiara B, et al. Treatment and outcomes of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke. Stroke. 2017;48:e343–61.

    PubMed  Google Scholar 

  46. Yeatts SD, Palesch YY, Moy CS, Selim M. High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocrit Care. 2013;19(2):257–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Selim M, Foster L, Moy C, et al. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomized, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2019;18(5):428–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Greer D, Ritter J, Helbok R, Badjatia N, Ko S-B, Guanci M, Sheth K. Impact of Fever Prevention in Brain-Injured Patients (INTREPID): study protocol for a randomized controlled trial. Neurocrit Care. 2021. https://doi.org/10.1007/s12028-021-01208-1.

    Article  PubMed  PubMed Central  Google Scholar 

  49. • Hanley DF, Thompson RE, Rosenblum M, et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIEIII): a randomized, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019. 393(10175):1021–1032. Pivotal study on placement of a catheter into the hemorrhage cavity

  50. Labib MA, Shah M, Kassam AB, et al. The safety and feasibility of image-guided BrainPath-mediated transsulcal hematoma evacuation: a multicenter study. Neurosurgery. 2017;80(4):515–24.

    Article  PubMed  Google Scholar 

  51. Bauer AM, Rasmussen PA, Bain MD. Initial single-center technical experience with the BrainPath system for acute intracerebral hemorrhage evacuation. Oper Neurosurg (Hagerstown). 2017;13(1):69–76.

    Article  Google Scholar 

  52. Diringer MN, Edwards DF. Admission to a neurologic/neurosurgical intensive care unit is associated with reduced mortality rate after intracerebral hemorrhage. Crit Care Med. 2011;29(3):635–40.

    Article  Google Scholar 

  53. Pfleger MJ, Hardee EP, Contant CF, Hayman AL. Sensitivity and specificity of fluid-blood levels for coagulopathy in acute intracerebral hematomas. AJNR Am J Neuroradiol. 1994;15:217–23.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The editors would like to thank Dr. John Brust for taking the time to review this article.

Author information

Authors and Affiliations

  1. Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN, USA

    Howard Kirshner & Matthew Schrag

Authors
  1. Howard Kirshner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Schrag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howard Kirshner.

Ethics declarations

Conflict of Interest

Howard Kirshner and Matthew Schrag each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Stroke

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kirshner, H., Schrag, M. Management of Intracerebral Hemorrhage: Update and Future Therapies . Curr Neurol Neurosci Rep 21, 57 (2021). https://doi.org/10.1007/s11910-021-01144-9

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11910-021-01144-9

Keywords

Search

Navigation